RGD Reference Report - The kallikrein-kinin system in diabetic nephropathy. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

The kallikrein-kinin system in diabetic nephropathy.

Authors: Tomita, H  Sanford, RB  Smithies, O  Kakoki, M 
Citation: Tomita H, etal., Kidney Int. 2012 Apr;81(8):733-44. doi: 10.1038/ki.2011.499. Epub 2012 Feb 8.
RGD ID: 7411620
Pubmed: PMID:22318421   (View Abstract at PubMed)
PMCID: PMC3498986   (View Article at PubMed Central)
DOI: DOI:10.1038/ki.2011.499   (Journal Full-text)

Diabetic nephropathy is the major cause of end-stage renal disease worldwide. Although the renin-angiotensin system has been implicated in the pathogenesis of diabetic nephropathy, angiotensin I-converting enzyme inhibitors have a beneficial effect on diabetic nephropathy independently of their effects on blood pressure and plasma angiotensin II levels. This suggests that the kallikrein-kinin system (KKS) is also involved in the disease. To study the role of the KKS in diabetic nephropathy, mice lacking either the bradykinin B1 receptor (B1R) or the bradykinin B2 receptor (B2R) have been commonly used. However, because absence of either receptor causes enhanced expression of the other, it is difficult to determine the precise functions of each receptor. This difficulty has recently been overcome by comparing mice lacking both receptors with mice lacking each receptor. Deletion of both B1R and B2R reduces nitric oxide (NO) production and aggravates renal diabetic phenotypes, relevant to either lack of B1R or B2R, demonstrating that both B1R and B2R exert protective effects on diabetic nephropathy presumably via NO. Here, we review previous epidemiological and experimental studies, and discuss novel insights regarding the therapeutic implications of the importance of the KKS in averting diabetic nephropathy.


Additional Information